T
301075
vs
S
Shanghai Composite
Over the past 12 months, Tibet Duo Rui Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +219% compared to the Shanghai Composite's +24% growth.
Stocks Performance
301075 vs Shanghai Composite
Performance Gap
301075 vs Shanghai Composite
Performance By Year
301075 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tibet Duo Rui Pharmaceutical Co Ltd
Glance View
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in research and development, manufacture, and sale of chemical preparations and their raw materials. The company is headquartered in Qamdo, Xizang and currently employs 299 full-time employees. The company went IPO on 2021-09-29. The firm's core product is sodium acetate ringer injection, which is mainly used to supplement body fluid, regulate electrolyte balance and correct acidosis. The firm's products also include its own products, compound electrolyte injection, compound mannitol injection and cefotaxime sodium for injection.